Exited investments

RetroSense Therapeutics (Michigan, USA) is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions. RetroSense’s approach creates photosensitivity in retinal ganglian cells via channelrhodopsin-2 expression restoring vision irrespective of which gene defect is responsible for vision loss. The company has successfully finished Ph1 clinical trials. Allergan (NYSE: AGN) acquired RetroSense Therapeutics in 2016 for a total consideration of $555M (including milestone payments).

Bonti (California, USA) is a rapidly growing biotechnology company engaged in the development of novel botulotoxin-based treatments. Bonti was founded by world-class experts with a proven success story at Allergan, one of the Fortune 500 fastest growing pharma companies having Botox™ as part of its product pipeline. The team has extensive neurotoxin, aesthetic and pain expertise, and is well-qualified to develop new treatment paradigms based on the novel neurotoxin platform and bring them to both aesthetic and therapeutic markets. The company was acquired by Allergan (NYSE: AGN) in Q4 2018 for $195M upfront plus undisclosed milestone payments.

An undisclosed investment, this clinical-stage company in the UK is developing a drug against a severe CNS disorder based on research from one of the top universities.